Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
Andre added that an unmet need remains in this setting despite the 2020 US approval and 2021 European approval of Keytruda as a first-line treatment ... price per infusion ranges from $8,877.20 for a ...
A global phase 3 trial is evaluating ASP-1929 photoimmunotherapy with Keytruda for recurrent HNSCC, involving around 400 patients. ASP-1929, an antibody-dye conjugate targeting EGFR, is activated by ...
Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...
Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...
MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...
There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...
Immune checkpoint inhibitors have been the MVP of cancer drugs in recent years. Merck’s Keytruda, for example, has been used against dozens of different cancers in millions of patients ...
MG introduced the Majestor three-row SUV at the Bharat Mobility Expo in India. The new SUV is a basically rebadged Maxus/LDV D90. MG describes the Majestor as the “tallest, longest, and widest ...
Your browser does not support the audio element. JSW-MG Motor India has announced the commencement of pre-bookings of the Cyberster at the ongoing Auto Expo 2025. The ...
Your browser does not support the audio element. JSW MG Motor India has showcased the M9 MPV at the ongoing Auto Expo 2025. This will be the second product sold via ...